Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R), the reference product, in patients with advanced cancer potentially sensitive to vinorelbine. Equivalence was demonstrated by a statistical comparison of both the areas under the curve (AUC) and maximum plasma concentrations (Cmax). The Company anticipates safety and full clinical results will be available during the first quarter of 2008. Results from this study will be submitted for presentation at an appropriate medical conference.

"We're very pleased with these results, which we believe will provide sufficient clinical data to support a Section 505(b)(2) New Drug Application," said Evan M. Levine, chief executive officer of ADVENTRX. "We have a meeting scheduled with the FDA in December to discuss our commercial manufacturing plans. After we receive the FDA's written comments, we intend to provide an update regarding our NDA timeline for ANX-530."

ANX-530 is a novel emulsion formulation of vinorelbine. Vinorelbine, marketed under the brand name Navelbine(R), also available as generic vinorelbine, is an anti-cancer agent approved to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million.

The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)...  Leadership speaker and business author Mary Kelly, Ph.D ., is helping members of the ... Photo - http://photos.prnewswire.com/prnh/20150420/199849 ... ... ... run a successful medical practice without pulling your hair out of your head or going bankrupt," ...
(Date:4/21/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ) announces ... filed with the U.K.,s Medicines and Healthcare ... Germany,s Federal Institute for Drugs and Medical ... Phase 2 program for the treatment of patients with ... include a cohort of patients with intrahepatic cholangiocarcinoma (ICC). ...
(Date:4/21/2015)... , April 21, 2015  The increase ... reforms the market for self-monitoring blood glucose (SMBG) ... limit the revenue potential for this market.  Availability ... and strained participants, profit margins. Photo ... analysis from Frost & Sullivan, US Self-monitoring ...
Breaking Medicine Technology:Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 3Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 4Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 5Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 2Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 3Noninvasive Glucose Monitors Creates Convergence with the Digital Health Era 4
... Cardiac Arrhythmia,Institute (TCAI) at St. David,s Medical Center ... sites in the nation to participate in an ... persistent atrial fibrillation. TCAI, an,international treatment, training and ... partnership between St. David,s Medical Center and,Texas Cardiovascular ...
... adults, VYVANSE taken once-daily significantly,improved the symptoms of ... Shire plc (LSE: SHP,Nasdaq: SHPGY), the global ... in the September issue of the Journal of,Clinical ... Disorder (ADHD) symptoms in adults within,the first week ...
Cached Medicine Technology:Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6
(Date:4/21/2015)... (PRWEB) April 21, 2015 Autocarsinsurancetips.com has ... low cost auto insurance plans by comparing ... drivers to find the best policies in their neighborhood. ... find the next best offer simply by comparing different ... by using online car insurance quotes. Insurance brokerage websites ...
(Date:4/21/2015)... Block Island, RI (PRWEB) April 21, 2015 ... the fountain of youth through fancy products and complex routines ... believes in skin care through suncare, not gimmicks, as the ... aging. Simply put, good suncare is more than just ... skin at all hours. Block Island Organics’ new Purifying ...
(Date:4/21/2015)... eMindful, the provider of ... Gallagher as senior vice president of sales. Gallagher has ... leadership roles with major health insurance carriers, health care ... he managed national accounts for The Vitality Group, a ... consistently a top producer, sales manager and executive for ...
(Date:4/21/2015)... 2015 A new study at a ... with peritoneal cancers like mesothelioma increased by 20 percent ... posted the results of the study. Click here ... at North Hampshire Hospital in Basingstoke performed a retrospective ... such as mesothelioma between 1994 and 2014. They ...
(Date:4/21/2015)... IN (PRWEB) April 21, 2015 ... employee benefits advisory organization, is pleased to welcome ... Firm. Since 1991, Mark Kunkle and Jeff Power ... of service earning the confidence of more than ... means innovative thinking, strategic planning, dedicated stewardship, ethical ...
Breaking Medicine News(10 mins):Health News:Online Auto Insurance Quotes Can Help Clients Save Money 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 3Health News:eMindful Continues to Expand Executive Leadership Team With Employee Benefits Sales Executive Michael Gallagher 2Health News:New Findings Highlight Value of Experience in Peritoneal Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2
... May 29 (HealthDay News) -- ,Adult survivors of childhood ... life because of the long-term physical effects of their ... data from the Childhood Cancer Survivor Study to assess ... experienced by more than 14,000 adult survivors of childhood ...
... , TUESDAY, May 29 (HealthDay News) -- Should the ... study suggests their inclusion may be warranted. The study ... are more likely to survive than those who refuse such ... lives of patients who receive smokers, lungs, however, tended to ...
... often first presents in newborn babies has been traced to ... London have found. The research, published online in ... a specific gene found in patients with the rare adrenal ... means affected children are unable to produce a hormone called ...
... mutation responsible for IMAGe syndrome, a rare disorder that stunts ... gene that causes BeckwithWiedemann syndrome, which makes cells grow too ... in the May 27 edition of the journal Nature Genetics, ... the rapid cell division that allows tumors to grow unchecked. ...
... and explanation" of the REMARK (Reporting Recommendations for Tumor ... of Oxford, UK and colleagues provide a detailed reference ... conducting, analyzing and reporting tumor marker prognostic studies. Writing ... in BMC Medicine ) the authors explain the ...
... 2012 Older adults who don,t get enough vitamin D ... be at increased risk of developing mobility limitations and disability, ... , "This is one of the first studies to look ... new mobility limitations or disability in older adults," said lead ...
Cached Medicine News:Health News:Emotional Woes May Last for Childhood Cancer Survivors 2Health News:Use of Smokers' Lungs for Transplant Has Pros, Cons 2Health News:Use of Smokers' Lungs for Transplant Has Pros, Cons 3Health News:Disease that stunts infants' growth traced to same gene that makes kids grow too fast 2Health News:Disease that stunts infants' growth traced to same gene that makes kids grow too fast 3Health News:Disease that stunts infants' growth traced to same gene that makes kids grow too fast 4Health News:Older adults may need more vitamin D to prevent mobility difficulties 2
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... workstation offers a broad menu, ... the mid-size lab that processes ... day. Like all SYNCHRON CX-S ... to use, easy to maintain ...
... for the high-volume lab, the SYNCHRON LX4201 ... performing up to 2,880 tests per hour. ... the SYNCHRON LX4201 with broad menu, speed ... you've come to expect from Beckman Coulter-innovative, ...
... technology to increase laboratory efficiency ... lower costs. It takes the ... features that you will not ... analyzer, including closed tube sampling ...
Medicine Products: